Re:
|
The
Quigley Corporation
|
|
Form
10-K for the Fiscal Year Ended December 31,
2008
|
|
Filed
March 9, 2009
|
|
Definitive
Proxy Statement on Schedule 14A
|
|
Filed
April 2, 2009
|
File Number:
000-21617
|
|
1.
|
Please
refer to your response to prior comment one. Please revise your
proposed disclosure to clarify what the charge for the $103,000
represents.
|
Amount
|
||||
Return
provision at December 31, 2007
|
$ | 296 | ||
Return
provision at December 31, 2008
|
1,427 | |||
Increase
in the return provision at
December 31, 2008
|
$ | 1,131 |
|
2.
|
Please
refer to the revised Statements of Cash Flows for the three year fiscal
period ended December 31, 2008 and the quarterly period ended March 31,
2008 in response to prior comment three. Please explain to us
why the cash flows related to the proceeds from the sale of Darius are not
presented within your 2008 investing activities for the fiscal year ended
December 31, 2008 and the interim periods of
2008.
|
Year
Ended
Dec 31, 2008 |
Year
Ended
Dec 31, 2007 |
Year
Ended
Dec 31, 2006 |
||||||||||
Cash
flows from operating activities:
|
||||||||||||
Net
loss
|
$ | (5,534 | ) | $ | (2,458 | ) | $ | (1,748 | ) | |||
Adjustments
to reconcile net loss to net cash provided by (used in) operating
activities:
|
||||||||||||
Loss
on asset impairment
|
100 | - | - | |||||||||
Depreciation
and amortization
|
745 | 996 | 1,327 | |||||||||
Gain
on disposal of health and wellness operations
|
(736 | ) | - | - | ||||||||
Loss
on the sales of fixed assets
|
17 | 20 | - | |||||||||
Sales
allowance and provision for bad debts
|
1,283 | (298 | ) | (341 | ) | |||||||
Inventory
valuation provision
|
832 | 438 | (680 | ) | ||||||||
(Increase)
decrease in assets and liabilities:
|
||||||||||||
Accounts
receivable
|
778 | 182 | 1,664 | |||||||||
Inventory
|
323 | (987 | ) | 318 | ||||||||
Prepaid
expenses and other current assets
|
(353 | ) | (48 | ) | 366 | |||||||
Other
assets
|
53 | 83 | (69 | ) | ||||||||
Accounts
payable
|
311 | (348 | ) | 114 | ||||||||
Accrued
royalties and sales commissions
|
41 | 328 | 451 | |||||||||
Accrued
advertising
|
(63 | ) | (770 | ) | (710 | ) | ||||||
Other
current liabilities
|
(1,847 | ) | 1,551 | 265 | ||||||||
Net
cash (used in) provided by operating activities
|
(4,050 | ) | (1,311 | ) | 957 | |||||||
Cash
flows from investing activities:
|
||||||||||||
Proceeds
for the sale of health and wellness operations
|
1,000 | - | - | |||||||||
Capital
expenditures
|
(200 | ) | (533 | ) | (697 | ) | ||||||
10 | - | 118 | ||||||||||
Net
cash flows provided by (used in) investing
activities
|
810 | (533 | ) | (579 | ) | |||||||
Cash
flows from financing activities:
|
||||||||||||
Principal
payments on debt
|
- | - | (1,464 | ) | ||||||||
Stock
options and warrants exercised
|
64 | 173 | 1,958 | |||||||||
Net
cash provided by financing activities
|
64 | 173 | 494 | |||||||||
Net
(decrease) increase in cash and cash equivalents
|
(3,176 | ) | (1,671 | ) | 872 | |||||||
Cash
and cash equivalents at beginning of period
|
15,133 | 17,757 | 16,885 | |||||||||
Less:
cash and cash equivalents of discontinued operations
at end of period reported as a component of assets of discontinued
operations
|
- | (953 | ) | - | ||||||||
Cash
and cash equivalents at end of period
|
$ | 11,957 | $ | 15,133 | $ | 17,757 | ||||||
Supplemental
disclosures of cash flow information:
|
||||||||||||
Interest
|
$ | - | $ | - | $ | 22 | ||||||
Taxes
|
$ | - | $ | - | $ | 89 |
Three
Months
Ended
March 31, 2009 |
Three
Months
Ended
March 31, 2008 |
|||||||
Cash
flows from operating activities:
|
||||||||
Net
loss
|
$ | (2,199 | ) | $ | (1,569 | ) | ||
Adjustments
to reconcile net loss to net cash provided by (used in) continuing
operations:
|
||||||||
Depreciation
and amortization
|
157 | 182 | ||||||
Gain
on disposal of health and wellness operations
|
- | (736 | ) | |||||
Sales
allowance and provision for bad debts
|
(536 | ) | (277 | ) | ||||
Inventory
valuation provision
|
(176 | ) | 23 | |||||
Changes
in operating assets and liabilities:
|
||||||||
Accounts
receivable
|
3,264 | 3,482 | ||||||
Inventory
|
(69 | ) | (180 | ) | ||||
Accounts
payable
|
(403 | ) | 94 | |||||
Accrued
royalties and sales commissions
|
(158 | ) | 34 | |||||
Accrued
advertising
|
(214 | ) | (163 | ) | ||||
Other
operating assets and liabilities, net
|
692 | (754 | ) | |||||
Net
cash provided by operating activities
|
358 | 136 | ||||||
Cash
flows from (used by) investing activities:
|
||||||||
Proceeds
for the sale of health and wellness operations
|
- | 1,000 | ||||||
Capital
expenditures
|
(71 | ) | (12 | ) | ||||
Net
cash flows provided by (used in) investing activities
|
(71 | ) | 988 | |||||
Cash
flows from financing activities:
|
||||||||
Stock
options and warrants exercised
|
- | 8 | ||||||
Net
cash provided by financing activities
|
- | 8 | ||||||
Net
increase in cash and cash equivalents
|
287 | 1,132 | ||||||
Cash
and cash equivalents at beginning of period
|
11,957 | 15,133 | ||||||
Cash
and cash equivalents at end of period
|
$ | 12,244 | $ | 16,265 | ||||
Supplemental
disclosures of cash flow information:
|
||||||||
Interest
|
$ | - | $ | - | ||||
Taxes
|
$ | - | $ | - |
Sincerely, | |||
|
|
/s/ Robert V. Cuddihy, Jr. | |
Robert V. Cuddihy, Jr. | |||
Interim Chief Financial Officer |
cc:
|
United
States Securities and Exchange
Commission
|